Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
BIO-TECHNE CORPORATION |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 66.04 USD | +2.58% | +4.63% | -20.32% | |
Financials (USD)
| Sales 2024 * | 1.18B | Sales 2025 * | 1.3B | Capitalization | 10.44B |
|---|---|---|---|---|---|
| Net income 2024 * | 216M | Net income 2025 * | 258M | EV / Sales 2024 * | 8,91x |
| Net Debt 2024 * | 44.33M | Net Debt 2025 * | 165M | EV / Sales 2025 * | 8,15x |
| P/E ratio 2024 * | 49,6x | P/E ratio 2025 * | 41,2x | Employees | 3,050 |
| Yield 2024 * | 0,48% | Yield 2025 * | 0,48% | Free-Float | 98.92% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +2.58% | ||
| 1 week | +4.63% | ||
| Current month | +4.99% | ||
| 1 month | +12.52% | ||
| 3 months | -12.54% | ||
| 6 months | -20.08% | ||
| Current year | -20.32% |
1 week
62.38
66.44
1 month
55.6366.44
Current year
51.7989.91
1 year
51.7989.91
3 years
51.79135.96
5 years
33.19135.96
10 years
19.99135.96
| Managers | Title | Age | Since |
|---|---|---|---|
Charles Kummeth
CEO | Chief Executive Officer | 62 | 2013 |
James Hippel
DFI | Director of Finance/CFO | 52 | 2014 |
Kim Kelderman
COO | Chief Operating Officer | 56 | 2018 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 67 | 2002 | |
Charles Kummeth
CEO | Chief Executive Officer | 62 | 2013 |
Randolph Steer
BRD | Director/Board Member | 73 | 1989 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.34% | 4 M€ | -16.71% | ||
| 4.34% | 77 M€ | -15.18% | ||
| 3.61% | 39 M€ | +13.56% | - | |
| 2.99% | 1,043 M€ | -6.24% | ||
| 2.99% | 5 M€ | -8.97% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-06 | 66.04 | +2.58% | 1,145,764 |
| 23-12-05 | 64.38 | -1.41% | 926,221 |
| 23-12-04 | 65.3 | +1.13% | 1,076,441 |
| 23-12-01 | 64.57 | +2.66% | 1,189,371 |
| 23-11-30 | 62.9 | -0.35% | 1,453,540 |
Delayed Quote Nasdaq, December 06, 2023 at 04:00 pm EST
More quotes
Bio-Techne Corporation specializes in the manufacture and marketing of products used in life science research. The group offers reagents and diagnostic tools for researchers, doctors, laboratories, pharmaceutical and biotechnology companies, etc. Net sales break down by family of products as follows:
- biological and chemical reagents and analysis tools (74.3%): proteins, antibodies, molecules, culture serums, tools for cell work, tools for the study of proteins, immunoassay tools, etc.;
- diagnostic and genomics products (25.7%): reagents and products used in blood analysis, nucleic acid analysis, tissue biopsy, gene analysis, cancer and genetic carrier screening, etc.
Net sales are distributed geographically as follows: the United States (56.5%), the United Kingdom (4.4%), Europe/Middle East/Africa (19.4%), China (10%), Asia/Pacific (6.4%), and other (3.3%).
Calendar
2024-02-05
- Q2 2024 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
66.04USD
Average target price
77.69USD
Spread / Average Target
+17.64%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.32% | 10 444 M $ | |
| +67.92% | 40 713 M $ | |
| +5.22% | 39 345 M $ | |
| -55.13% | 30 731 M $ | |
| -26.13% | 28 435 M $ | |
| +38.19% | 22 100 M $ | |
| -26.35% | 21 964 M $ | |
| -0.25% | 16 910 M $ | |
| -13.70% | 11 278 M $ | |
| -7.90% | 10 294 M $ |
